Q3 2025 · 13F-HR
Catalys Pacific, LLCholdings as filed
Filed 2025-11-14 · accession 0001104659-25-112029
$351.4M
Reported value
2
Positions
2025-09-30
Period end
The Brief · Catalys Pacific, LLC · Q3 2025
AI · grounded in 13F
Catalys Pacific, LLC established a new position in Mineralys Therapeutics, Inc. MLYS valued at $337.6M. The fund also initiated a new stake in Phathom Pharmaceuticals, Inc. PHAT worth $13.7M. These two holdings comprise the fund's total assets under management of $351.4M.
Holdings as filed
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.